Ignite Creation Date:
2024-06-16 @ 11:50 AM
Last Modification Date:
2024-10-26 @ 3:31 PM
Study NCT ID:
NCT06445517
Status:
RECRUITING
Last Update Posted:
2024-06-07
First Post:
2024-05-31
Brief Title:
Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and RelapsedRefractory B-Cell Lymphoma
Sponsor:
InSilico Medicine Hong Kong Limited
Organization:
InSilico Medicine Hong Kong Limited
Study Overview
Official Title:
A Phase 1 Open-label Multicenter First-in-Human Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Efficacy of ISM8207 Monotherapy in Patients With Advanced Solid Tumors or RelapsedRefractory B-Lymphoid Malignancies
Status:
RECRUITING
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The goal of this clinical trial is to study ISM8207 in participants with advanced solid tumors and relapsedrefractory B-cell lymphoma The primary objective is to evaluate the safety and tolerability of ISM8207 orally administered in participants with advanced solid tumors and relapsedrefractory B-cell lymphoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None